Weight-loss and diabetes drugs reduced the risk of developing Alzheimer’s, an independent study published Monday showed. The ...
Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...
A new study led by Western researchers found frequent treatment with intranasal oxytocin – a hormone in the brain associated ...
Eli Lilly has chalked ... TRAILBLAZER-ALZ 2 trial, which showed that Kisunla slowed cognitive and functional decline by 35% compared with placebo on the integrated Alzheimer's Disease Rating ...
Early research suggests GLP-1 drugs could prevent or treat Alzheimer's Disease. Results from a big clinical trial could soon ...
GlobalData analysts are predicting an Alzheimer’s disease market boom, tipping its value across major regions to increase ...
A study shows GLP-1 weight-loss drugs reduce Alzheimer’s risk but increase arthritis, kidney, and pancreas issues.
Bloomberg on MSN12d
Alzheimer’s drugs eyed as next big obesity-like opportunityInvestors seeking the next obesity-like market opportunity will be closely watching developments related to treatments for Alzheimer’s disease in 2025.
As evidence has mounted that new diabetes and weight loss drugs can provide a variety of health benefits, the FDA has ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback